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Abstract
Over two million Americans are afflicted with schizophrenia, a debilitating mental health disorder
with a unique symptomatic and epidemiological profile. Genomics studies have hinted towards
candidate schizophrenia susceptibility chromosomal loci and genes. Modern proteomic tools,
particularly mass spectrometry and expression scanning, aim to identify both pathogenic-revealing
and diagnostically significant biomarkers. Only a few studies on basic proteomics have been
conducted for psychiatric disorders relative to the plethora of cancer specific experiments. One
such proteomic utility enables the discovery of proteins and biological marker fingerprinting
profiling techniques (SELDI-TOF-MS), and then subjects them to tandem mass spectrometric
fragmentation and de novo protein sequencing (MALDI-TOF/TOF-MS) for the accurate
identification and characterization of the proteins. Such utilities can explain the pathogenesis of
neuro-psychiatric disease, provide more objective testing methods, and further demonstrate a
biological basis to mental illness. Although clinical proteomics in schizophrenia have yet to reveal a
biomarker with diagnostic specificity, methods that better characterize the disorder using
endophenotypes can advance findings. Schizophrenia biomarkers could potentially revolutionize its
psychopharmacology, changing it into a more hypothesis and genomic/proteomic-driven science.
Schizophrenia proteomics: biomarkers on the 
path to laboratory medicine?
Affecting nearly 1% of the world's population, schizo-
phrenia is marked by chronic psychosis and social, occu-
pational, behavioral, and cognitive impairment. This
debilitating psychiatric disorder requires a disproportion-
ate share of medical resources due to its early onset and
chronic and severe nature. Schizophrenia is a lifelong dis-
order that usually manifests after puberty and before 25
years of age, with equal risks across gender. The illness is
episodic and places the sufferer at an increased risk of sui-
cide.
Proteomics studies have focused extensively on cancer
diagnosis and non-invasive monitoring, primarily via
serum samples. Many have revealed potential biomarkers
or biochemical molecules that identify a specific disease
state and are capable of being detected or measured. For
example, tumor marker CA125 (MUC16) provides useful
information on disease resistance, treatment response,
and even early detection in ovarian cancer screening, and
efforts are underway for its clinical application [1].
Not surprisingly, the standards for viable biomarkers are
high. Ideally, a diagnostic marker meets seven conditions:
1) it detects a fundamental feature of the disease with high
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sensitivity and specificity; 2) is validated in post-mortem
confirmed cases; 3) standardized with sound bioinfor-
matics; 4) specific for the disease compared with related
disorders; 5) reliable in many testing environments/labs;
6) noninvasive; 7) simple to perform; and 8) inexpensive
[adapted from [2]].
Despite the significant rates of self-harm behavior associ-
ated with schizophrenia, its relatively high prevalence in
the general population and the existence of a substantial
untreated population, no biomarker has yet been discov-
ered for the disorder.
This article describes the ability of proteomic approaches
to accurately identify novel biomarkers, which may pro-
vide a substantial insight into schizophrenia pathogene-
sis. In addition, proteomic investigations could lead to the
discovery of diagnostic and prognostic biomarkers and
potential new molecular targets for drug development.
Class prediction methods may validate potential biomar-
kers, and class discovery may reveal distinct etiologies and
subtypes for better categorization. Applying the same pro-
teomic methods to clinically accessible fluids (e.g., serum,
cerebrospinal fluid, and urine) would place invaluable
objective analytical power in the hands of the clinician.
The clinical significance of basic science research in schiz-
ophrenia is effective biomarker discovery, efficient assay-
ing techniques, a high level of statistical discrimination,
and tailored drug development. However, such research
also involves serious ethical considerations, particularly
in the application of detection technologies. In addition,
logistical challenges may impede the progress of clinical
proteomics in schizophrenia.
Genomics
Early investigations into the genetic component of schiz-
ophrenia utilized linkage studies as their primary analysis
[see [3] for a review]. In pedigree studies, the location of
many DNA markers were computed, compared in dis-
eased and disease-free cohorts, and a probability of statis-
tical significance (i.e., LOD score) was computed
confirming or denying linkage. Meta-analyses of several
linkage studies suggested correlations with some chromo-
somal regions, particularly 1q, 2q, 6q, and 11q; however,
none approached an acceptable genome-wide signifi-
cance [4]. While they have successfully mapped genes for
monogenic or Mendelian disorders [5], linkage studies are
inadequate for complex multi-factorial disorders like
schizophrenia.
Later research employed association studies that com-
pared allelic frequencies in schizophrenia and control
groups. Essentially, it tested for linkage disequilibrium
where two alleles or genetic markers are rarely separated
by crossover. To minimize the ethnic variance on allelic
frequency, family-based association studies were per-
formed where at least one member was afflicted with
schizophrenia. They revealed mixed results; however, the
central areas where genetic aberration was mostly likely
present, namely dopamine, serotonin, and NMDA recep-
tors, showed little or no association [3].
Genetic studies have mapped many susceptibility loci as
well as large chromosomal aberrations in schizophrenia
[4,6,7]. However, the emergence of high-throughput
microarray profiling allowed the rapid and economical
assaying of thousands of gene expression levels. The pre-
frontal cortex, Brodmann area 9 (BA 9), was identified as
a prominent site of dysfunction based on substantial neu-
roimaging, clinical, and postmortem studies, and has
been the recent focus of microarray investigations [8,9].
Studies revealed the under expression of pre-synaptic
markers [10], major metabolic pathways [11], and oli-
godendrocyte development and maturation genes [12].
Although genomic data may uncover novel information
or corroborate current theories in schizophrenia patho-
genesis, finding useful markers may be within the scope of
proteomics. Gene expression data do not consistently cor-
relate with protein expressions, and cannot identify post-
transcriptional and post-translational modifications,
major modulators of protein function, and presumably
pathogenesis [13,14]. Moreover, the majority of schizo-
phrenia microarray studies were based on post-mortem
brain tissues, a clinically inaccessible medium.
Proteomics
In the "post-genomic" era, the natural progression is
towards interrogating the main effectors of physiological
functions – proteins. The major genomic projects of the
last decade have shaped proteome-wide sequencing, map-
ping, and analysis. For example, the creation of the
Human Proteome Organization's Human Brain Proteome
Project to foster the effective international communica-
tion of brain related proteomic data [15]. Complex dis-
eases are now rapidly investigated by novel high-
throughput biochemical inquires to uncover disease
dynamics, clinical markers, and drug targets.
Contrary to the genome, the proteome is composed of an
active array of molecules constantly being modified and
with special localization. Proteomic approaches are able
to characterize post-translational modifications, a
method by which the cell dynamically and quickly modi-
fies protein function and regulates both creation and deg-
radation in response to cellular perturbations (e.g.,
disease provocation). Protein profiling and identification
techniques using mass spectrometry (MS) and bioinfor-
matics can lead to the discovery, identification, and char-Diagnostic Pathology 2006, 1:11 http://www.diagnosticpathology.org/content/1/1/11
Page 3 of 13
(page number not for citation purposes)
acterization of protein biomarkers differentially expressed
in the diseased states versus the control.
Protein profiling
Similar to gene mRNA expression profiling, several pro-
tein profiling techniques emerged in the last decade that
did not require a priori knowledge of candidate genes or
proteins. From variations of gel electrophoresis to the
advent of peptide specific mass spectrometry, each modal-
ity confers another method of differential protein expres-
sion analysis. Profiling the proteomes of diseased and
healthy tissues allows for the discovery of peptide or pro-
tein molecular change, which potentially reveals informa-
tion on pathogenesis or diagnosis, or both.
2-Dimensional Gel Electrophoresis (2D-GE)
Initial proteomic studies relied on 2D-GE, which sepa-
rates proteins based on two factors: isoelectric point and
molecular weight. The process is complicated, burden-
some, and certainly not robust. It was never intended to
serve as a biomarker discovery wizard; rather, its use was
limited to pathogenic discovery. Edgar et al. [16] applied
this approach to the hippocampal proteome of schizo-
phrenia and control groups to reveal 108 differentially
expressed proteins. The most significantly under-
expressed protein in their schizophrenic hippocampus
was subjected to peptide digestion and N-terminal pep-
tide sequencing. Based on a simple protein database
search, their query revealed the protein to be diazepam-
binding inhibitor (DBI). Reports indicate that DBI can
bind to a GABAA recognition site and therefore down-reg-
ulate the action of gamma-aminobutyric acid (GABA), an
inhibitory neurotransmitter system altered in schizophre-
nia [17,18].
Edgar et al. [19] further identified three differentially
expressed proteins in schizophrenia: manganese superox-
ide dismutase (MnSOD) was under-expressed; and col-
lapsing response mediator protein 2 (CRMP-2) and t-
complex protein 1 (TCP-1) were over-expressed. MnSOD
catalyzes the dismutation of superoxide anion (O2
-) into
water (H2O) and hydrogen peroxide (H2O2). In nervous
tissue, it may protect the survival of cell membranes [20].
CRMP-2 regulated axonal growth and polarity [21,22]. Its
over-expression may explain the vast neural interconnec-
tions in the schizophrenic brain.
TCP-1 is a chaperone protein that aides in proper protein
folding and arrangement [23]. It has protective properties
in the brain, preventing stress-induced apoptotic path-
ways in neurons [24]. 2D-GE analysis of fetuses with
Down syndrome uncovered a significant decrease of TCP-
1 in the second trimester, which may explain the disor-
der's early pathology [25]. However, it is over expressed in
schizophrenia hippocampal tissue [19]. The authors sug-
gested a possible alteration in cytoskeleton turnover in
schizophrenia. Perhaps the mechanisms of a cytological
aberration is by way of the post-translation modification
– oxidation/nitration.
Oxidative stress is particularly implicated in neurodegen-
erative diseases like Alzheimer's [26] and Parkinson's dis-
eases [27]. Gene expression studies with schizophrenia
have consistently identified oxidation related transcripts.
Theories have postulated that when the production of
harmful oxidants exceeds the rate of anti-oxidant com-
pounds, macromolecules such as DNA and proteins
become the targets of oxidative attack, which signals sub-
sequent death. Moreover, Japanese scientists were the first
to identify proteins targets for nitration in the brains of
rats, which included TCP-1 [28]. The original research
methodology did not allow for post-translational modifi-
cation testing; the state of TCP-1 in schizophrenic hippoc-
ampal tissue therefore remains unknown.
Chromosomal location is another feature of the study that
sheds light on schizophrenia. Three of the four character-
ized proteins were mapped to chromosomal arm 6q.
Their vicinity reveals a region important in schizophrenia
and confirms the susceptibility of loci found by the link-
age study [29].
Despite the informative studies using 2D-GE with schizo-
phrenia, this modality proved very limited. Three impor-
tant issues were raised that have instigated investigations
into other resolution measures. First, 2D-GE analysis has
limited reproducibility. Second, weakly soluble proteins
cannot be easily resolved. Third, only a tiny portion of the
proteome can be effectively stained. It is especially diffi-
cult for low-level expressed proteins and those masked by
greater expression within a similar molecular weight or
isoelectric point, or both.
Matrix Assisted Laser Desorption Ionization (MALDI)
The field of proteomics advanced dramatically with the
advent of mass spectrometric (MS) analysis for peptides.
There are four components to mass spectrometry. First,
the ion source generates ionized peptides or proteins from
the sample. Second, the mass analyzer sortes and resolves
proteins based on their mass/charge (m/z) ratio. Third, the
ion detector spots the ions and composes data on the ion
m/z, quantity, and time of flight (TOF), or the time it took
to reach the detector. Finally, bioinformatic analysis inter-
prets the raw data into meaningful results (e.g., differen-
tial protein profiling).
MALDI is considered the standard of MS instruments. A
special chemical matrix is applied over the sample and
allowed to condense. After lasers activate the matrix, the
energy is conferred to the peptides or proteins, and theyDiagnostic Pathology 2006, 1:11 http://www.diagnosticpathology.org/content/1/1/11
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are sent on a direct trajectory to the detector in a gas phase.
This aids in two types of analysis: the creation of a peak
pattern or signature specific to the disease, and in identifi-
cation by inference. In the latter, the protein complex is
usually proteolitically digested before ionization, creating
specific peptide cleavages. After a MS run, and in a process
called peptide mass fingerprinting, the peptide masses
obtained from the m/z ratio are queried into several data-
bases (e.g., UCSF's MS-fit and ExPASy's Aldente) to infer
protein identification.
Jiang et al. [30] employed MALDI technology to analyze
cerebral spinal fluid, and found significant down-regula-
tion of apolipoprotein A-IV (apo AIV). However, given the
paucity of published works correlating the CNS and this
apolipoprotein, they were unable to extend their finding.
Apo AIV is a glycoprotein secreted by the intestine [31],
which signals the body's satiety after consuming lipids. In
rats, apo AIV mRNA and protein were found in the
hypothalamus and their concentrations correlated with
feeding states [32]. The under-expression of apo AIV in
schizophrenia suggests a correlation between the
increased risk of weight gain and insulin resistance, either
attributable to the disease or as a side effect of anti-psy-
chotics [33].
Cerebral spinal fluid sampling presents a major challenge.
Several highly expressed proteins, particularly serum albu-
min, transferin, and immunoglobulins, often mask lower
abundance proteins. This study performed few purifica-
tion measures to fractionate and better resolve the sample
protein population. SELDI, a new generation of MS anal-
ysis, offers better resolution with built in chromatogra-
phy. Researchers at Novartis in Switzerland have
identified an optimized protocol for sample preparation
and SELDI analysis for CSF studies [34].
Surface Enhanced Laser/Desorption Ionization (SELDI)
As with all spectrometric analysis, samples must be treated
in some part before ionization. SELDI technology, a vari-
ation of MALDI, relies on ProteinChip arrays. Each chip
offers a unique chromatographic surface for selective pro-
tein capture. For example, the IMAC ProteinChip incorpo-
rates an immobilized metal, often copper, as its vehicle for
affinity capture. The CM10 ProteinChip is a weak-cation
exchanger array, while the Q10 is a strong-anion exchange
array.
Researchers at the ProteinChip manufacturer Ciphergen,
in association with the NYU School of Medicine, applied
SELDI analysis to schizophrenic postmortem prefrontal
cortex brain tissue [35]. This approach sought to harvest
spectral peak intensities and m/z values to develop signa-
tures capable of differentiating schizophrenia from non-
disease states. Using the three aforementioned surface
chemistries, they maximized their total protein peaks to
1597. Forty-five peak differences were found to be statisti-
cally significant.
Class prediction using the decision rule algorithms where
the informative peaks in the training set were used to per-
form leave-one-out cross validation. When incorporated
into a statistical model from the training data set, the test-
ing data set had a sensitivity of 69% and a specificity of
70%. In other words, 69% of schizophrenics were cor-
rectly identified using the signature, and 70% of normal
individuals were appropriately recorded. These values fall
short from cancer signatures in the range of 90–100% [36-
40]. However, it affirms the heterogeneous etiology of
schizophrenia and hints at the potential of SELDI meth-
odology.
Nonetheless, SELDI technology has inherent limits. There
can be competition between non-informative and inform-
ative peaks based on abundance and molecular weight.
The proteins are competing to bind with the chromato-
graphic molecules. Greater abundance proteins may con-
ceal those with lower abundance. In addition, proteins
with the same mass as the target protein may augment the
mass intensity that is tested for.
High-throughput protein identification & characterization
Studies that solely identify protein peaks for signatures or
peak patterns do not provide information on schizophre-
nia pathogenesis and drug targets. Only after the identifi-
cation of differentially expressed proteins can molecular
mechanisms be unraveled. Moreover, if performed on a
clinically inaccessible medium, such as brain tissue, they
serve no function in the discovery of diagnostic biomark-
ers.
Although peptide mass fingerprinting is one method of
protein identification, it often requires extensive and
often complex purification, and it tenders an interpreted
protein match by peptide masses rather than by
sequences. Edman degradation, although offering amino
acid data, is a slow task that cannot process N-terminally
modified peptides, has limited sequence length (about
50–60 amino acids residues), and a low efficiency (e.g.,
missed cleavages).
Collision Induced Disassociation (CID)
MS has evolved to incorporate tandem mass spectrometric
(MS/MS) technology that permits effective sequencing.
The MALDI-TOF/TOF-MS technology is a cutting-edge
proteomic utility with direct amino acid sequencing and
characterization capabilities. Essentially, there are two
TOF instruments separated by a fragmentation center,
which allows for traditional MS for profiling and MS/MS
signals for high-throughput identification.Diagnostic Pathology 2006, 1:11 http://www.diagnosticpathology.org/content/1/1/11
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The sample loading spots are subdivided into many fields
and each field can be ionized independently. Moreover,
they can be separately subjected to high-energy CID to
induce fragmentation with optimized laser intensity and
reflectron properties based on the protein molecular
weight of interest [41]. Complementary fragments of the
ion series are recorded when perceived by the MS detector.
Data analysis software interprets uninterrupted high-
energy CID fragment spectra into amino acid sequences.
Identification of the protein is performed by querying the
sequences against the protein databases (e.g., the NCBI
nr) with database-searching algorithms (i.e., the probabil-
ity based Matrix Science Mascot) [42].
As opposed to low-energy fragmentation methods,
MALDI-TOF/TOF-MS is capable of high-energy CID,
which can uniquely generate immonium ion fragments
and cleave side chains of isobaric amino acids essential to
distinguishing leucine and isoleucine. It yields unambigu-
ous and reproducible sequence assignments vital to char-
acterizing the proteins of interest.
Functional-complex study
No published schizophrenia study has yet employed the
profiling and sequencing properties of tandem mass spec-
trometric analysis. However, several studies have demon-
strated the potential of this technology in determining the
complexities of the dynamic proteome. Sequence analysis
can detect post-translation modifications such as acetyla-
tion, trimethylation, phosphorylation, sulfation, and N-
or O-glycosylation [43,44]. It offers complex information
such as ubiquitylation [45], which could reveal sites for
repair, transcriptional regulation, and apoptosis.
This system can interrogate, identify, and characterize gly-
cosylphosphatidylinositol (GPI) anchored proteins that
are integrated into the plasma membrane [46]. The prion
protein (PrP) is a prominent member of the GPI anchored
protein family. Given that such proteins are involved in
cell adhesion, differentiation, and host-pathogen interac-
tions [47], it is a vital area of interest for schizophrenia.
The Nogo-66 receptor gene (RTN4R) is a GPI anchored
protein implicated in axonal growth inhibition, and a
candidate for a schizophrenia susceptibility gene [48].
Even after proper isolation, these proteins are virtual inac-
cessible using conventional MS techniques. However, tan-
dem technology with CID amino acid sequencing can
recognize the protein's GPI attachment site (the Ω site),
structure, and aberrations.
Reduced gene and protein expression of Reelin (RELN)
[47] and up-regulation of neural cell adhesion molecule
(NCAM) [49] is noted in schizophrenia. Recently, East-
wood and Harrison [50] confirmed reduced RELN mRNA
expression in schizophrenic interstitial white matter neu-
rons in the hippocampal formation and dorsolateral pre-
frontal cortex. Similarly, NCAM is over-expressed in the
hippocampus and prefrontal cortex [51].
RELN is a secretory protease produced by GABAergic
interneurons and binds to pyramidal neurons or GABAer-
gic interneurons actively expressing the disabled-1 gene
(DAB-1) product. Most of RELN's signaling pathways are
mediated through DAB-1, including neuronal migration,
synaptic plasticity, transmission, and survival. NCAM is a
surface protein structurally similar to immunoglobulin
and fibronectin. It is implicated in homophilic binding
for cellular adhesion and the same processes as RELN.
These two glycoproteins are excellent targets for MS/MS
characterization. Using affinity purification for the two
molecules, the samples can be processed for protein com-
plex identification using mass spectrometry. Protein bind-
ing partners can also be identified as a part of a complex
when targeting known signal transduction domains (e.g.,
SH2 and Grb2).
This technique may reveal protein complexes within inter-
action networks. However, not only do dynamic post-
translational modifications (e.g., ECAM) further compli-
cate MS probing, background sample contaminants may
produce false positives. Two-dimensional liquid chroma-
tography systems can resolve composite protein mixtures
based on chromatofocusing and reversed-phase chroma-
tography [see [52] for further information].
Selective scanning by location
In the aforementioned studies using brain tissues, sam-
ples were homogenized and lysed, and the protein super-
natant subjected to MS. Various cellular molecular
profiles are pooled together losing descriptive spatial
information and interfering with distinct profiling.
Although the RELN study used immunohistochemistry
and autoradiography to visualize its specific expression,
those methods can only interrogate one protein per array
and the user must have a priori information to perform
them. However, to gain further insight into the molecular
pathology of neuropsychiatric disease we can employ
selective cellular proteomics.
One such technology, laser capture microdissection
(LCM), isolates precise cellular, extra-cellular, and even
sub-cellular areas for subsequent molecular analysis [53].
Pure populations of proteins (or other macromolecules)
can be isolated under direct visualization using a micro-
scope. Laser pulses transfer the biological material to a
film. Downstream, the molecular concentrations are
within the sensitivity of SELDI analysis.Diagnostic Pathology 2006, 1:11 http://www.diagnosticpathology.org/content/1/1/11
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Another medium, layered expression scanning (LES), has
multiple membrane layers [54]. Biomolecules from tissue
sections can be captured by each layer that retains its spa-
tial orientation. There are two operating environments. In
the open system, it can process macromolecules in a non-
specific fashion. In the closed system, membranes are pre-
treated with an affinity binder (e.g., antibody) for individ-
ual protein localization; however, there can be numerous
protein interrogations per a single tissue section.
While there are currently no published works applying
these techniques to schizophrenic tissues, LCM and LES
can provide substantial information about the pathogen-
esis of schizophrenia. Major brain regions, including the
temporal lobe and executive function areas, are priority
targets. Each of the six cortical layers can be independently
examined per Brodmann area providing cellular level data
on protein expression. Integrating the data in a bioinfor-
matic platform to yield a validated biochemical model for
schizophrenia is yet another realizable scientific feat.
Clinical implications
Schizophrenia is a truly debilitating disorder that merits
further proteomic inquiry. A PubMed search shows that of
the 7,987 articles on the topic of proteomics, only 19 cor-
respond to schizophrenia. In contrast, 1,339 were on can-
cer proteomics (the other papers were largely
methodological reports). Regarding the limited findings
already generated, and in anticipation of further studies
that utilize a larger sample size, selective instrumentation,
and quality controls, the problem lies in translating the
data into clinically useful tools.
Translational research merges basic science and clinical
research for optimal therapeutic benefit. The wealth of
proteomic findings in the pipeline must be processed for
clinical applicability to the effected patient population. To
process clinical proteomics in schizophrenia where pro-
teomic strategies are married to the discipline of medi-
cine, we must understand the disease profile, etiology and
pathogenesis, diagnostic strategies, and finally clinical
management. In each medical realm, proteomics has a
unique and revolutionizing role.
Clinical profile
Clinical symptoms of schizophrenia usually begin in late
adolescence or early adulthood. They are generally
grouped into three broad categories: "positive" or "nega-
tive" based on the pathological effects of normal func-
tions, and "cognitive impairments." Over time, positive
and negative symptoms tend to be episodic and to vary in
intensity.
Positive symptoms
These include symptoms that are considered exaggera-
tions or distortions of normal functions: psychosis, false
beliefs (delusions; 90% incidence in all subjects), percep-
tion of something when nothing in fact exists in the per-
ceptual field (hallucinations; 50% incidence), and bizarre
behaviors [55].
Negative symptoms
Negative symptoms are deficit states in which fundamen-
tal emotions are either weakened or entirely deficient,
including blunted affect, anhedonia (inability to experi-
ence pleasure from normal activities), apathy (loss of
interest and motivation), social withdrawal, and alogia
(diminished speech content). They have an earlier and
more subtle onset, and are less episodic than psychotic
symptoms.
Cognitive symptoms
Schizophrenia may encompass disturbances in cognition,
usually related to attention and concentration, learning
and memory, psychomotor speed (e.g., prolonged reac-
tion time), and executive processing (e.g., formulating
and initiating plans, abstract thinking, and problem solv-
ing).
Schizophrenia is a devastating psychotic disorder because
it destroys the social functioning and employability of
patients. Negative symptoms and cognitive impairment
are generally the disabling mechanisms of schizophrenia.
A patient may no longer have the ability to concentrate on
and take pleasure from work, studies, or leisure activities.
Moreover, the patient's lack of medical insight further hin-
ders their ability to take advantage of effective coping
strategies, which, in turn, can further aggravate social
withdrawal, depression, and the risk of suicide.
Etiology
Schizophrenia is a multifaceted disorder manifested by
both genetic and environmental factors. A plethora of
twin and adoption studies have suggested major genetic
influences on the pathogenesis of schizophrenia; how-
ever, a MZ concordance of about 50% [56] also indicated
the involvement of environmental factors. These family
studies reveal that schizophrenia is a complex genetic dis-
order, akin to diabetes and cancer, with not one causative
gene but rather multiple genes contributing to susceptibil-
ity. In other words, it is a polygenetic disease. Moreover,
there are presumably environmental factors that contrib-
ute to the onset of the disease.
The vulnerability-stress-coping model frames psychotic and
affective disorders from a biopsychosocial perspective
[57-59]. Vulnerabilities may predispose the individual to
the disorder, while environmental stressors can poten-Diagnostic Pathology 2006, 1:11 http://www.diagnosticpathology.org/content/1/1/11
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tially modulate (trigger) the expression of symptoms in
vulnerable bodies-minds.
In schizophrenia, vulnerability may include genetic predis-
position, birthing complications, and CNS viral infec-
tions. Stressful life events (e.g., being fired from work,
terminating a relationship, or moving into a new environ-
ment) and biological stressors (e.g., substance abuse) may
exacerbate the illness by triggering the emergence or reoc-
currence of symptoms. However, protective coping mecha-
nisms can safeguard vulnerable persons by weakening or
eliminating symptoms.
The vulnerability-stress-coping model demonstrates the com-
posite mechanism of schizophrenia and provides a useful
diagram for optimal combination therapy for clinical
management. However, it does dramatically complicate
any proteomic screening. Studies using samples from tis-
sue collections (e.g., the Stanley Brain Research Labora-
tory and Brain Collection) risk skewing their findings by
factoring in confounding drug, storage, and various stres-
sor effects.
Pathogenesis
Despite extensive efforts through histological, neuro-
chemical, neuroimaging, and gene and protein expression
studies, the biomedical community has yet to uncover a
definitive diagnostic neuropathology for schizophrenia.
However, several important findings do collectively direct
our knowledge of schizophrenia pathology and contrib-
ute to medical interventions. Initially they were directed
by pharmacologic manipulation; however, there has been
progress towards uncovering genetic biological markers
using genomic and proteomic strategies. They have pro-
gressed the understanding of schizophrenia from psycho-
somatic origins to a brain disease subject to objective
study.
At present, the medical community is familiar with path-
ological alterations of the dopamine (DA), serotonin, ace-
tylcholine (ACh), and glutamate systems. Studies into the
use of substances that induce psychosis (e.g., ampheta-
mines) have revealed enhanced reuptake of DA [60].
These findings initiated the dopamine hypothesis, which
states hyperactive DA transmission in schizophrenia, per-
haps in response to stress. The brain is essentially overly
sensitive (hyperactive) to stimuli and fails to properly reg-
ulate its response through normal inhibitory mecha-
nisms. To potentially explain negative symptoms, brain
imaging studies have revealed prefrontal cortex (PFC) dys-
function [61,62], specifically a regional deficit in DA neu-
rotransmission [63].
The current view of the dopamine hypothesis relates
hyperactive subcortical and hypoactive cortical DA neuro-
transmission to positive symptoms and negative-cogni-
tive impairments, respectively. However, the theory is
contested. For example, the total inhibition of DA does
not fully mitigate the positive symptoms of schizophrenia
[64], suggesting additional pathological disturbances.
Recent genomic and proteomics studies have moved away
from a purely disrupted DA model to that of oxidative
stress and synaptic pathology, which may cause dysregu-
lation of several neurotransmitters and neuronal apopto-
sis [see [65] for a review]. Various presumed susceptibility
genes and their products have been identified: neuregulin-
1 (NRG1), dysbindin (DTNBP1), regulator of G-protein
signaling 4 (RGS4), catechol-o-methyltransferase
(COMT), proline dehydrogenase (PRODH) and dis-
rupted-in-schizophrenia 1 (DISC1) [66]. However, there
are clinical applicability issues with diagnostic specificity
[67] and the small effect size [68].
Diagnosis
Given the lack of an objective and definitive diagnostic
test, clinicians currently look beyond the organ and dis-
ease-specific approach in psychiatric diagnosis. Clinicians
interview patients to watch for abnormal behaviors, ascer-
tain risk factors, and record a personality profile. The cli-
nician actively listens to the patient and establishes a
comfortable atmosphere to reveal pertinent information.
Diagnostic classification manuals such as the American
Psychiatric Association's Diagnostic and Statistical Man-
ual of Mental Disorders (DSM) [69] serve as provisional
constructs allowing the international biomedical commu-
nity to employ inclusion and exclusion criteria based on
potential deviations from normal psychological function-
ing. In fact, they explicitly serve not to educate about a
particular etiology or pathology; rather, they reasonably
classify disorders by symptom profiles for effective univer-
sal communication. Manuals essentially offer standards
for symptom definition and differential diagnosis. None-
theless, they may create false perceptions of known dis-
crete disorder entities that are far from the multifarious
and overlapping reality.
Current criteria
Current DSM diagnostic criteria for schizophrenia include
at least one month of active symptoms (at least one of
bizarre delusions or auditory hallucinations, or two or
more individual positive and/or negative symptoms) and
a six-month period of social/occupational dysfunction or
independent-care impairments. Patients may have brief
psychotic reactions for one to six months that resemble
schizophrenia, known as schizophreniform disorder, but
rapidly remit and do not reoccur. The diagnosis, however,
may in fact be mood disorders with psychotic features.Diagnostic Pathology 2006, 1:11 http://www.diagnosticpathology.org/content/1/1/11
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In addition to inclusion principles, the DSM establishes
exclusionary guidelines for primary mood disorders with
psychotic features (e.g., unipolar or bipolar depression)
and psychosis-induced by the physiological properties of
a general medical condition or chemical substances.
Classification
The current scheme of schizophrenia classification, like
for other psychiatric disorders, stems from the clinician's
observation of gross behaviors. Consequently, it is rather
imprecise and does not necessarily correlate with genetic
pathology. A movement for molecular class discovery in
complex disorders is in place where genetic observations
can subtype or differentially cluster groups based on gene
or protein expression or susceptibility genes or their prod-
ucts. As opposed to the class prediction or supervised
learning where knowledge of the conditions are known to
yield an expression signature, class discovery or unsuper-
vised learning uncovers patterns with no prior knowledge
of traits and assembles clusters. For example, extensive
phenotypic characterizations and diagnostic groups were
identified for inflammatory bowel disease, permitting
productive genetic analysis [70]. In addition, supervised
and unsupervised analysis was applied to leukemia DNA
microarray data [71]. It demonstrated an ability to distin-
guish between acute and chronic leukemia and a special
gene subset for leukemia forms.
By recognizing the imperfect relationship between geno-
type and phenotype in psychiatry, Gould and Gottesman
[72] anticipated the discovery of endophenotypes  to
improve genetic studies. In a reductionist approach, this
classification is a simplified measure for a single neuronal
circuit with fewer genes or proteins. Five criteria were
identified for an endophenotype: 1) it is associated with
illness in the general population; 2) heritable; 3) state
independent (regardless of illness activity); 4) cosegre-
gates with illness in families; and 5) the endophenotype
identified in probands is found in unaffected relatives at a
higher rate than in the general population.
Given the spectrum of neuronal circuits implicated to
date, a complicated disorder like schizophrenia is presum-
ably composed of multiple endophenotypes. Studies
employing this approach create more homogenous sub-
types, rather than merely altering their defining observa-
tions. For example, working memory is considered an
endophenotype in schizophrenia [73]. They found a pop-
ulation of schizophrenia patients had a significantly dis-
turbed working memory and demonstrated that it was a
partially inheritable deficit. Furthermore, it can be
assessed using conventional tests (e.g., Wisconsin Card
Sorting, backward and forward digit span, and digit sym-
bol substitution).
Applying powerful class discovery to schizophrenia in
association with specific endophenotypic descriptors may
reveal signatures and true classification strata. Preliminary
data from Bowden et al. [74] indicated the ability to sub-
group schizophrenia by age using gene expression data
from peripheral blood lymphocytes. Appling this to mode
of death, duration of illness, medication, drug use, alco-
hol abuse, smoking patterns, genetic relative risk, and
related classifiers provides valuable information. How-
ever, applying it to specific schizophrenia endopheno-
types could shape validated classifications, more precisely
identify pharmaceutical targets, and prove immensely
important in the future of schizophrenia molecular biol-
ogy studies.
Differential diagnosis
The development of biomarkers capable of differential
diagnosis would be a paramount achievement in medi-
cine. In clinical practice, it is essential to uncover the
underpinnings of psychosis, discover the etiology and
pathology, and then design and implement sound clinical
management. Whether the disorder is schizophrenia,
affective, or organic in nature plays a significant role in
determining the proper treatment. Patients that present
with disturbed behavior and/or mentation may be hur-
riedly and incorrectly deemed psychiatric, when in fact the
psychotic symptoms are secondary to general medical
conditions or substance abuse. Moreover, mood disorders
may present with poor reality testing but require treat-
ment of the mood disturbances and psychosis; however,
they are difficult to differentiate from schizophrenia.
Central nervous system stimulant and depressant-induced
intoxication and withdrawal may encompass psychotic
features that complicate diagnostic efforts. Chronic abuse
of psychoactive substances, such as amphetamines and
cocaine, stimulate dopamine neurotransmission and trig-
ger hallucinations and delusions. Users of phencyclidine
(PCP) may experience psychosis, agitation, and violent
behaviors [75]. It is imperative to run toxicology blood
tests, sometimes beyond the standard drug screens, based
on clinical observations.
When proteomic studies implicate two testing groups –
schizophrenia and control – their biomarker findings may
represent biological compounds with similar altered
expression patterns in related disorders. This is especially
pertinent for disorders with symptoms stemming from a
common etiology. For example, serum studies in schizo-
phrenia that isolate inflammatory markers may have sim-
ilar findings to disorders with inflammation (e.g., in
reference to differential diagnosis, bipolar disorder,
Alzheimer's disease, Parkinson's disease, head trauma,
and brain tumors).Diagnostic Pathology 2006, 1:11 http://www.diagnosticpathology.org/content/1/1/11
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Examining samples from patients with disorders of com-
mon and exclusive endophenotypes provides the best
insight into each disorder component – the factor that the
clinical will treat. For explanation purposes, let us hypo-
thetically start with multiple endophenotypes. Biological
samples from individuals with schizophrenia, bipolar dis-
order, major depressive disorder, and normal controls are
examined by protein profiling. In each diseased group,
sub-populations are defined based on individual assess-
ments of each endophenotype. Class prediction may iden-
tify protein peaks that discriminate the various groups
based on disease classification. However, analysis with
endophenotype descriptors may reveal markers that best
correlate with endophenotypic dysfunction and thus the
treatment target.
Clinical management
The ultimate goals of schizophrenia clinical management
are to reduce or eliminate all associated symptoms,
improve socio-behavioral functioning, foster reintegra-
tion into society, prevent the relapse of psychotic epi-
sodes, and treat or prevent (further) co-morbidity.
Clinicians employ a combination of pharmacological
(neuroleptic) and psychosocial interventions according to
the vulnerability-stress-coping model. The first line of coping
is usually medicinal options for the suppression of symp-
toms and control of disturbed behavior. Psychosocial
modalities contribute to improve patient insight and
compliance, while promoting the development and
implementation of personal goals.
Since the 1950s and until recently, first-generation antip-
sychotic medications have been the staple of schizophre-
nia treatment (e.g., chlorpromazine and haloperidol).
The neuroleptic mode of action is presumably DA block-
ade in the mesolimbic-mesocortical system – DA receptor
antagonism [76]. However, if the antipsychotic action and
the antischizophrenic action were one and the same,
schizophrenic symptoms would cease just hours after
administration. This is not the case; rather, gradual
improvement is observed over a period of weeks. The
antischizophrenic properties of neuroleptics may be
attributable to a tolerance mechanism caused by long-
term therapy. Essentially, DA neurotransmission returns
to a more normal state, significantly improving positive
symptoms.
Most patients taking first-generation antipsychotic agents
have some response, with 20% experiencing complete
remission [77-80]. However, neuroleptic-induced DA
blockage in the basal ganglia and more generally the
nigrostriatial system contributes to extrapyramidal reac-
tionary movement disorders [81].
Over the past 15 years, clozapine has served as the progen-
itor of second-generation (atypical) antipsychotic drugs.
All second-generation drugs share the DA blockade mech-
anism of the first-generation; however, they have selective
affinity for DA and similar receptors, and also implicate
additional neurotransmission systems (e.g., serotonin).
Clinically, their efficacy is established by reducing
extrapyramidal side effects, and therefore improving med-
ication compliance, treating refractory schizophrenia, and
reducing negative symptoms and cognitive impairments.
However, clozapine is never prescribed as the first antip-
sychotic because it presents with an increased incidence of
seizures and agranulocytosis – an immune system disor-
der marked by a decrease of granulocytes – and thus
patients are prone to chronic bacterial infections [82].
Newer second-generation drugs, such as risperidone,
olanzapine, quetiapine, and ziprasidone, have at an equal
or greater clinical efficacy and better adverse effect profile
than first generation drugs, and a lower incidence of
agranulocytosis than clozapine [83,84]. All neuroleptics
operate to reduce positive symptoms; however, second-
generation drugs have a greater effect on negative symp-
toms and cognitive function.
Drug discovery
Drug discovery for psychiatric disorders has been largely
haphazard to date; however, a systematic approach is pro-
gressing. The procedures for drug discovery in schizophre-
nia include target discovery and validation, dose
selection, clinical end points, and responder identifica-
tion. First, two types of biomarkers are identified: disease-
specific and drug activity markers. The former character-
izes the disease, and the latter monitors drug interactions.
Second, toxicity prediction is implemented for dose selec-
tion. Third, surrogate end points are used to predict
important clinical outcomes. For example, blood pressure
is a surrogate outcome for a stroke. Substituting clinical
end points (e.g., survival) for surrogate end points (e.g.,
lowered blood pressure) allows for a reduced sample size
yet maintains statistical power and a shorter patient mon-
itoring term. Finally, the study identifies the patient pop-
ulations that have received the intended benefit.
Proteomics has the ability to significantly affect drug dis-
covery in schizophrenia by three principle means. First,
protein profiling and identification techniques may iden-
tify novel pharmaceutical targets and co-regulated com-
pounds. Second, proteomics can measure current drug
responses. In effect, it can aid with efficacy and toxicity by
screening animal models. Finally, it can function as a
means of surrogate end point only if the compounds in
question have a true association to mortality or the mor-
bidity in question.Diagnostic Pathology 2006, 1:11 http://www.diagnosticpathology.org/content/1/1/11
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Unfortunately, the very disease symptoms that demand
enhanced drugs – cognitive and negative symptoms – do
not have proper animal models. Chen, Lipska, and Wein-
berger [85] demonstrated the impossibility of trying to
recapitulate the full spectrum of schizophrenia in animal
models. Although schizophrenia-like behaviors were
shown in hypothesis-driven genetic mouse models, par-
ticularly via disrupted DA or glutamine neurotransmis-
sion, cognitive ability and emotional intelligence is
difficult to test in animal models. Nonetheless, neuro-
electrophysiology is a promising tool for clinically testing
schizophrenic patients and animal models with schizo-
phrenia-like abnormal information processing [86].
Ethical considerations
The prospect of genetic testing for schizophrenia has gen-
erated a range of ethical, legal, and social issues that must
be considered. A vital part of schizophrenia research is the
protection of vulnerable individuals from unreasonable
risk and to prevent the exploitation of research partici-
pants. The US Department of Health and Human services
has established a regulatory code for the protection of
human subjects. However, as a set of guidelines, they do
not specifically bar certain controversial lines of schizo-
phrenia testing. That naturally leads to ethical quandaries
concerning the ability of mentally disabled persons to offer
informed consent, and the impact of withdrawing drug
treatment or permitting drug-naïve patients to participate
in biomedical research. These topics have been discussed
at length elsewhere [87-89]. The discussion below briefly
focuses on issues involving the use of psychiatric biomar-
kers for eugenics and sterilization and as an employment
screening tool (e.g., disqualifier).
Reproductive freedom
Contemporary Western bioethics considers human dig-
nity to be intrinsic to all human individuals [90]. In the
United States, beliefs and attitudes associated with mental
illness have dramatically changed with the understanding
of biological pathogenesis and the implementation of
combination treatment options. However, a survey has
revealed a general negative perception of individuals with
genetic disabilities among international geneticists, as
well as government involvement in premarital testing and
sterilization in China [91].
China has been under intense scrutiny since the passage of
the Maternal and Infant Health Care Law in 1995.
Although it prohibits prenatal genetic diagnosis for the
purpose of sex selection, it does permit the use of eugenic
statutes for the systematic abortion of offspring suspected
of having serious medical disorders, including mental ill-
ness [92]. Furthermore, the law authorizes the steriliza-
tion of genetic carriers. China could conceivably apply
these provisions to any genetic susceptibility found for
schizophrenia.
Chinese scientists must be made to realize that their stud-
ies will not be published, access to foreign funding
restricted, international collaboration halted, and the
nation's reputation jeopardized if these eugenics policies
are not abolished and legally binding and effective moni-
toring systems are established for biomedical research.
Otherwise, the fruits of genomic and proteomic investiga-
tion could lead to the reproductive suppression of the very
individuals we are attempting to understand and treat.
Occupational discrimination
The development of diagnostic technology in schizophre-
nia could also be used as a tool for occupational screen-
ing. Selection for jobs that require exceptionally
specialized training (e.g., astronauts) could eventually
involve genetic screening for schizophrenia. While Presi-
dential Executive Order (13145) prohibits the discrimina-
tion of federal employees based on genetic information,
certain exceptions could permit this practice (e.g., interfer-
ence with job duties). Quick [93] has argued the need for
federal legislation given the highly variable application of
laws in state court cases. Currently, thirty-one states ban
workplace genetic discrimination [94].
This screening and potential genetic discrimination could
even extend to intellectual positions (e.g., medical doc-
tors). Studies have shown that employers are increasingly
making use of genetic testing [95]. We need to fill the cur-
rent void with professional guidelines that frame work-
place genetic screening. Conceivably, it may implement
voluntary screening procedures, a system of informed
consent, and mutually agreed outcomes.
Conclusion
Schizophrenia is associated with greater co-morbidity and
lowered life expectancy. The disease process, antipsy-
chotic interventions, and socioeconomics foster very
unhealthy habits (e.g., poor diet, smoking, drug abuse)
and disease (e.g., obesity, diabetes, hyperlipidemia, cardi-
ovascular disease, cataracts). These factors contribute to
an overall decline in health, interfere with clinical man-
agement, and place a strain on the medical infrastructure.
Scientists and their funding sources are realizing the
potential impact of psychiatry genomics and proteomics
for relieving the burdens associated with major psychiatry
disorders.
Proteomic utilities have just begun to define schizophre-
nia with molecular biology detail. Conventional modali-
ties in proteomics have restrictive limitations, preventing
the interrogation of proteins under a certain molecular
weight (e.g., the majority of neuropeptides), those foundDiagnostic Pathology 2006, 1:11 http://www.diagnosticpathology.org/content/1/1/11
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in or associated with the plasma membrane (e.g., GPI
anchored proteins), and the post-translation modifica-
tions heavily employed in brain tissue. Ultimately, tech-
nology provides insight into only a small portion of the
proteome. However, advances in mass spectrometric
measures, namely tandem MS technology, offer the
potential to identify and characterize novel biomarkers.
Unlike cancer proteomics, schizophrenia proteomics
faces several obstacles before it can be used in laboratory
medicine. We must adopt an integrative approach to stud-
ying schizophrenia in order to generate proper classifica-
tions (e.g., endophenotypes and unsupervised class
discovery), distinguish causality from mere association
(e.g., putative susceptibility versus true biomarkers), uti-
lize quality control measures (e.g., standardize practices
and variation measurements), and take a proactive stance
on the improper use of schizophrenia genetics.
Schizophrenia remains a disabling condition, but
progress in the genomic and proteomic sciences, more
efficacious pharmacology for negative symptoms and cog-
nitive dysfunction, and greater societal awareness and
appreciation of mental health issues may help alleviate
this problem. The discovery of schizophrenia biomarkers
will likely revolutionize the field of psychiatry, as did the
introduction of psycho-pharmaceuticals, but such
progress is still substantially in the future.
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